Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort

Trial Profile

Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Endoxifen (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Atossa Genetics
  • Most Recent Events

    • 11 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to an Atossa Genetics media release.
    • 01 Aug 2018 According to an Atossa Genetics media release, Study is now open for enrollment in Sweden.
    • 26 Jun 2018 According to an Atossa Genetics media release, enrollment in this trial is anticipated to be completed by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top